Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain

Neurobiology of Disease

Volumn 58, Issue , 2013, Pages 19-28

  Khasabova, Iryna A ^a   Holman, Michelle ^a   Morse, Tim ^a   Burlakova, Natalya ^a   Coicou, Lia ^b   Harding Rose, Catherine ^a   Simone, Don A ^a   Seybold, Virginia S ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Anandamide; Cancer; CAY10455; Dorsal root ganglion; Fatty acid amide hyrdolase; Fatty acid binding protein; Hydrolysis; Hyperalgesia; Neuron; Transport; Uptake; URB597

Indexed keywords

ANANDAMIDE; BMS 309403; CAY 10455; CHOLESTEROL; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 5; OMDM 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BONE TUMOR; CALCANEOUS BONE TUMOR; CANCER CELL CULTURE; CANCER PAIN; CELL LEVEL; COCULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG POTENTIATION; DRUG UPTAKE; ENZYME ACTIVITY; EVOKED RESPONSE; FIBROSARCOMA; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; INTRAPLANTAR DRUG ADMINISTRATION; MALE; MECHANICAL STIMULATION; MONOTHERAPY; MOUSE; NOCIFENSIVE BEHAVIOR; NONHUMAN; PRIORITY JOURNAL; SENSORY NERVE CELL; SPINAL GANGLION;

AEA; ANANDAMIDE; CANCER; CANNABINOID TYPE-1 RECEPTOR; CAY10455; CB1R; DORSAL ROOT GANGLION; DRG; FAAH; FABP; FATTY ACID AMIDE HYDROLASE; FATTY ACID AMIDE HYRDOLASE; FATTY ACID BINDING PROTEIN; HYDROLYSIS; HYPERALGESIA; I.PL; INTRAPLANTAR; MΒC; METHYL-Β-CYCLODEXTRIN; NEURON; PBS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA; PHOSPHATE BUFFERED SALINE; PPARΑ; TRANSIENT RECEPTOR POTENTIAL VANILLOID-TYPE 1; TRANSPORT; TRPV1; UPTAKE; URB597;

ANIMALS; ARACHIDONIC ACIDS; BENZAMIDES; BRAIN NEOPLASMS; CANNABINOID RECEPTOR ANTAGONISTS; CARBAMATES; CELLS, CULTURED; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; ENZYME INHIBITORS; FIBROSARCOMA; FLUORESCENT DYES; GANGLIA, SPINAL; HYPERALGESIA; INDOLES; LACTONES; MALE; MICE; MICE, INBRED C3H; PAIN; PAIN THRESHOLD; POLYUNSATURATED ALKAMIDES; SENSORY RECEPTOR CELLS; STATISTICS, NONPARAMETRIC; TRITIUM;

EID: 84878496660     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.04.018     Document Type: Article

References (69)

1. Abramov A.Y., Ionov M., Pavlov E., Duchen M.R. Membrane cholesterol content plays a key role in the neurotoxicity of β-amyloid: implications for Alzheimer's disease. Aging Cell. 2011, 10:595-603.
2. Agarwal N., Pacher P., Tegeder I., Amaya F., Constantin C.E., Brenner G.J., Rubino T., Michalski C.W., Marsicano G., Monory K., Mackie K., Marian C., Batkai S., Parolaro D., Fischer M.J., Reeh P., Kunos G., Kress M., Lutz B., Woolf C.J., Kuner R. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. 2007, 10:870-879.
3. Bari M., Battista N., Fezza F., Finazzi-Agrò A., Maccarrone M. Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. J. Biol. Chem. 2005, 280:12212-12220.
4. Bari M., Paradisi A., Pasquariello N., Maccarrone M. Cholesterol-dependent modulation of type 1 cannabinoid receptors in nerve cells. J. Neurosci. Res. 2005, 81:275-283.
5. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 1997, 277:1094-1097.
6. Bennett G.J., Xie Y.K. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1998, 33:87-107.
7. Biswas K.K., Sarker K.P., Abeyama K., Kawahara K., Iino S., Otsubo Y., Saigo K., Izumi H., Hashiguchi T., Yamakuchi M., Yamaji K., Endo R., Suzuki K., Imaizumi H., Maruyama I. Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis. Hepatology 2003, 38:1167-1177.
8. Cain D.M., Wacnik P.W., Turner M., Wendelschafer-Crabb G., Kennedy W.R., Wilcox G.L., Simone D.A. Functional interactions between tumor and peripheral nerve: changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain. J. Neurosci. 2001, 21:9367-9376.
9. Chicca A., Marazzi J., Nicolussi S., Gertsch J. Evidence for bidirectional endocannabinoid transport across cell membranes. J. Biol. Chem. 2012, 287:34660-34682.
10. Clohisy D.R., Ogilvie C.M., Carpenter R.J., Ramnaraine M.L. Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts. J. Orthop. Res. 1996, 14:2-6.
11. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996, 384:83-87.
12. Deutsch D.G., Glaser S.T., Howell J.M., Kunz J.S., Puffenbarger R.A., Hillard C.J., Abumrad N. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J. Biol. Chem. 2001, 276:6967-6973.
13. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372:686-691.
14. Di Pasquale E., Chahinian H., Sanchez P., Fantini J. The insertion and transport of anandamide in synthetic lipid membranes are both cholesterol-dependent. PLoS One 2009, 4:e4989.
15. Djouhri L., Koutsikou S., Fang X., McMullan S., Lawson S.N. Spontaneous pain, both neuropathic and inflammatory, is related to frequency of spontaneous firing in intact C-fiber nociceptors. J. Neurosci. 2006, 26:1281-1292.
16. Fegley D., Kathuria S., Mercier R., Li C., Goutopoulos A., Makriyannis A., Piomelli D. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:8756-8761.
17. Fowler C.J. Anandamide uptake explained?. Trends Pharmacol. Sci. 2012, 33:181-185.
18. Fowler C.J., Tiger G., Ligresti A., López-Rodríguez M.L., Di Marzo V. Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis - a difficult issue to handle. Eur. J. Pharmacol. 2004, 492:1-11.
19. Fowler C.J., Naidu P.S., Lichtman A., Onnis V. The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. Br. J. Pharmacol. 2009, 156:412-419.
20. Fu J., Bottegoni G., Sasso O., Bertorelli R., Rocchia W., Masetti M., Guijarro A., Lodola A., Armirotti A., Garau G., Bandiera T., Reggiani A., Mor M., Cavalli A., Piomelli D. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat. Neurosci. 2012, 15:64-69.
21. Furuse S., Kawamata T., Yamamoto J., Niiyama Y., Omote K., Watanabe M., Namiki A. Reduction of bone cancer pain by activation of spinal cannabinoid receptor 1 and its expression in the superficial dorsal horn of the spinal cord in a murine model of bone cancer pain. Anesthesiology 2009, 111:173-186.
22. Glaser S.T., Abumrad N.A., Fatade F., Kaczocha M., Studholme K.M., Deutsch D.G. Evidence against the presence of an anandamide transporter. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4269-4274.
23. Guindon J., Hohmann A.G. The endocannabinoid system and pain. CNS Neurol. Disord. Drug Targets 2009, 8:403-421.
24. Honore P., Rogers S.D., Schwei M.J., Salak-Johnson J.L., Luger N.M., Sabino M.C., Clohisy D.R., Mantyh P.W. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000, 98:585-598.
25. Huggins J.P., Smart T.S., Langman S., Taylor L., Young T. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 2012, 153:1837-1846.
26. Jayamanne A., Greenwood R., Mitchell V.A., Aslan S., Piomelli D., Vaughan C.W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol. 2006, 147:281-288.
27. Jhaveri M.D., Richardson D., Robinson I., Garle M.J., Patel A., Sun Y., Sagar D.R., Bennett A.J., Alexander S.P., Kendall D.A., Barrett D.A., Chapman V. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 2008, 55:85-93.
28. Kaczocha M., Glaser S.T., Deutsch D.G. Identification of intracellular carriers for the endocannabinoid anandamide. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6375-6380.
29. Kaczocha M., Lin Q., Nelson L.D., McKinney M.K., Cravatt B.F., London E., Deutsch D.G. Anandamide externally added to lipid vesicles containing-trapped fatty acid amide hydrolase (FAAH) is readily hydrolyzed in a sterol-modulated fashion. ACS Chem. Neurosci. 2012, 3:364-368.
30. Kaczocha M., Vivieca S., Sun J., Glaser S.T., Deutsch D.G. Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors. J. Biol. Chem. 2012, 287:3415-3424.
31. Khasabova I.A., Stucky C.L., Harding-Rose C., Eikmeier L., Beitz A.J., Coicou L.G., Hanson A.E., Simone D.A., Seybold V.S. Chemical interactions between fibrosarcoma cancer cells and sensory neurons contribute to cancer pain. J. Neurosci. 2007, 27:10289-10298.
32. Khasabova I.A., Khasabov S.G., Harding-Rose C., Coicou L.G., Seybold B.A., Lindberg A.E., Steevens C.D., Simone D.A., Seybold V.S. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J. Neurosci. 2008, 28:11141-11152.
33. Khasabova I.A., Chandiramani A., Harding-Rose C., Simone D.A., Seybold V.S. Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical hyperalgesia in a model of bone cancer pain. Pharmacol. Res. 2011, 64:60-67.
34. Khasabova I.A., Xiong Y., Coicou L.G., Piomelli D., Seybold V. Peroxisome proliferator-activated receptor α mediates acute effects of palmitoylethanolamide on sensory neurons. J. Neurosci. 2012, 32:12735-12743.
35. Kilsdonk E.P., Yancey P.G., Stoudt G.W., Bangerter F.W., Johnson W.J., Phillips M.C., Rothblat G.H. Cellular cholesterol efflux mediated by cyclodextrins. J. Biol. Chem. 1995, 270:17250-17256.
36. Kinsey S.G., Long J.Z., O'Neal S.T., Abdullah R.A., Poklis J.L., Boger D.L., Cravatt B.F., Lichtman A.H. Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J. Pharmacol. Exp. Ther. 2009, 330:902-910.
37. Kinsey S.G., Naidu P.S., Cravatt B.F., Dudley D.T., Lichtman A.H. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. Pharmacol. Biochem. Behav. 2011, 99:718-725.
38. La Rana G., Russo R., Campolongo P., Bortolato M., Mangieri R.A., Cuomo V., Iacono A., Raso G.M., Meli R., Piomelli D., Calignano A. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J. Pharmacol. Exp. Ther. 2006, 317:1365-1371.
39. La Rana G., Russo R., D'Agostino G., Sasso O., Raso G.M., Iacono A., Meli R., Piomelli D., Calignano A. AM404, an anandamide transport inhibitor, reduces plasma extravasation in a model of neuropathic pain in rat: role for cannabinoid receptors. Neuropharmacology 2008, 54:521-529.
40. Lichtman A.H., Hawkins E.G., Griffin G., Cravatt B.F. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J. Pharmacol. Exp. Ther. 2002, 302:73-79.
41. Ligresti A., Morera E., Van Der Stelt M., Monory K., Lutz B., Ortar G., Di Marzo V. Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem. J. 2004, 380:265-272.
42. Liu M., Huang W., Wu D., Priestley J.V. TRPV1, but not P2X, requires cholesterol for its function and membrane expression in rat nociceptors. Eur. J. Neurosci. 2006, 24:1-6.
43. Maccarrone M., Dainese E., Oddi S. Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem. Sci. 2010, 35:601-608.
44. Maccarrone M., Bernardi G., Agrò A.F., Centonze D. Cannabinoid receptor signaling in neurodegenerative diseases: a potential role for membrane fluidity disturbance. Br. J. Pharmacol. 2011, 163:1379-1390.
45. Mao J., Price D.D., Mayer D.J., Lu J., Hayes R.L. Intrathecal MK-801 and local nerve anesthesia synergistically reduce nociceptive behaviors in rats with experimental peripheral mononeuropathy. Brain Res. 1992, 576:254-262.
46. Mercadante S., Radbruch L., Caraceni A., Cherny N., Kaasa S., Nauck F., Ripamonti C., De Conno F., Steering Committee of the European Association for Palliative Care (EAPC) Research Network Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002, 94:832-839.
47. Mitchell V.A., Greenwood R., Jayamanne A., Vaughan C.W. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models. Clin. Exp. Pharmacol. Physiol. 2007, 34:1186-1190.
48. Mitrirattanakul S., Ramakul N., Guerrero A.V., Matsuka Y., Ono T., Iwase H., Mackie K., Faull K.F., Spigelman I. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 2006, 126:102-114.
49. Muller C.P., Stephany D.A., Winkler D.F., Hoeg J.M., Demosky S.J., Wunderlich J.R. Filipin as a flow microfluorometry probe for cellular cholesterol. Cytometry 1984, 5:42-54.
50. Muthian S., Nithipatikom K., Campbell W.B., Hillard C.J. Synthesis and characterization of a fluorescent substrate for the N-arachidonoylethanolamine (anandamide) transmembrane carrier. J. Pharmacol. Exp. Ther. 2000, 293:289-295.
51. Nicholson A.M., Ferreira A. Increased membrane cholesterol might render mature hippocampal neurons more susceptible to beta-amyloid-induced calpain activation and tau toxicity. J. Neurosci. 2009, 29:4640-4651.
52. Oddi S., Bari M., Battista N., Barsacchi D., Cozzani I., Maccarrone M. Confocal microscopy and biochemical analysis reveal spatial and functional separation between anandamide uptake and hydrolysis in human keratinocytes. Cell. Mol. Life Sci. 2005, 62:386-395.
53. Oddi S., Fezza F., Pasquariello N., De Simone C., Rapino C., Dainese E., Finazzi-Agrò A., Maccarrone M. Evidence for the intracellular accumulation of anandamide in adiposomes. Cell Mol Life Sci. 2008, 65:840-850.
54. Oddi S., Fezza F., Pasquariello N., D'Agostino A., Catanzaro G., De Simone C., Rapino C., Finazzi-Agrò A., Maccarrone M. Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins. Chem. Biol. 2009, 16:624-632.
55. Ortar G., Ligresti A., De Petrocellis L., Morera E., Di Marzo V. Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem. Pharmacol. 2003, 65:1473-1481.
56. Patterson M.C., Hendriksz C.J., Walterfang M., Sedel F., Vanier M.T., Wijburg F., NP-C Guidelines Working Group Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol. Genet. Metab. 2012, 106:330-344.
57. Piomelli D., Tarzia G., Duranti A., Tontini A., Mor M., Compton T.R., Dasse O., Monaghan E.P., Parrott J.A., Putman D. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev. 2006, 12:21-38.
58. Potenzieri C., Brink T.S., Pacharinsak C., Simone D.A. Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation. J. Neurophysiol. 2008, 100:2794-2806.
59. Pristerá A., Okuse K. Building excitable membranes: lipid rafts and multiple controls on trafficking of electrogenic molecules. Neuroscientist 2012, 18:70-81.
60. Pristerà A., Baker M.D., Okuse K. Association between tetrodotoxin resistant channels and lipid rafts regulates sensory neuron excitability. PLoS One 2012, 7:e40079.
61. Renganathan M., Cummins T.R., Waxman S.G. Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. J. Neurophysiol. 2001, 86:629-640.
62. Rigaud M., Gemes G., Barabas M.E., Chernoff D.I., Abram S.E., Stucky C.L., Hogan Q.H. Species and strain differences in rodent sciatic nerve anatomy: implications for studies of neuropathic pain. Pain 2008, 136:188-201.
63. Russo R., LoVerme J., La Rana G., D'Agostino G., Sasso O., Calignano A., Piomelli D. Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. Eur. J. Pharmacol. 2007, 566:117-119.
64. Sagar D.R., Kendall D.A., Chapman V. Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br. J. Pharmacol. 2008, 155:1297-1306.
65. Schengrund C.L. Lipid rafts: keys to neurodegeneration. Brain Res. Bull. 2010, 82:7-17.
66. Spradley J.M., Guindon J., Hohmann A.G. Inhibitors of monoacylglycerol lipase, fatty-acid amide hydrolase and endocannabinoid transport differentially suppress capsaicin-induced behavioral sensitization through peripheral endocannabinoid mechanisms. Pharmacol. Res. 2010, 62:249-258.
67. Storch J., Thumser A.E. Tissue-specific functions in the fatty acid-binding protein family. J. Biol. Chem. 2010, 285:32679-32683.
68. Wacnik P.W., Eikmeier L.J., Ruggles T.R., Ramnaraine M.L., Walcheck B.K., Beitz A.J., Wilcox G.L. Functional interactions between tumor and peripheral nerve:morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J. Neurosci. 2001, 21:9355-9366.
69. Wacnik P.W., Baker C.M., Herron M.J., Kren B.T., Blazar B.R., Wilcox G.L., Hordinsky M.K., Beitz A.J., Ericson M.E. Tumor-induced mechanical hyperalgesia involves CGRP receptors and altered innervation and vascularization of DsRed2 fluorescent hindpaw tumors. Pain 2005, 115:95-106.